alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 32.2

CERTIFICATION PURSUANT TO 
18 U.S.C. SECTION 1350 
AS ADOPTED PURSUANT TO 
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





|In connection with the annual report of Naturewell, Incorporated (the "Registrant") on Form 10-K for the period ended June 30, 2011 as filed with the Securities and Exchange Commission on the date hereof (the "Report") the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|                                                                                                                                                                                                                                                                                                                                                                                                       
|                                                                                                                                                                                                                                                                                                                                                                                                       
|                                                                                                                                                                                                                                                                                                                                                                                                       
|Dated:  October 13, 2011
The State of 

Fourth Court of Appeals

San Antonio, Texas

July 3, 2014

No. 04-13-00831-CR

Douglas Oneil BARNES,

Appellant

v.

The STATE of Texas,

Appellee

From the 198th Judicial District Court, Bandera County, Texas

Trial Court No. CR13-001

Honorable M. Rex Emerson, Judge Presiding

ORDER

On March 18, 2014, appellant’s court-appointed counsel filed a brief and a first amended 

motion to withdraw in accordance with Anders v. California, 386 U.S. 738 (1967). On March 21, 

2014, we issued an order advising appellant of his right to file his own brief and giving appellant 

forty-five (45) days from the date of our order to file any pro se brief. Appellant did not file a pro 

se brief within the time provided. This appeal was therefore ready to be submitted to the court.

However, on June 25, 2014, before this appeal was set for submission, the Texas Court of 

Criminal Appeals instructed that court-appointed counsel who files an Anders brief must “take 

concrete measures to initiate and facilitate the process of actuating his client’s right to review the 

appellate record, if that is what his client wishes.” Kelly v. State, No. 0702-13, 2014 WL 

2865901, at *3 (Tex. Crim. App. 2014). The Court of Criminal Appeals further instructed that 

when an appellant files a motion for access to the appellate record, the court of appeals must 

specify the procedure for an appellant to obtain the record in that particular case. Id., at *4.

In light of the posture of this appeal, appellant is advised that if he desires to 

exercise his right to review the appellate record, he must file a written request for access to 

the record with this court by July 17, 2013. Any such request must reference this appeal and 

be mailed to:

Fourth Court of Appeals

300 Dolorosa, Suite 3200

San Antonio, Texas 78232
If appellant timely requests access to the record, the deadline to file appellant’s pro se 

brief will be reset. Otherwise, this case will be set for submission to the court.

_________________________________

Karen Angelini, Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said 

court on this 3rd day of July, 2014.

___________________________________

Keith E. Hottle

Clerk of Court
Exhibit








Exhibit 10.1


AMENDMENT NO. 5
TO
EMPLOYMENT AGREEMENT
AMENDMENT, dated February 15, 2017 (“Amendment”), made to the Employment Agreement dated as of March 31, 2008, as amended by Amendment No. 1 thereto effective as of December 31, 2008, Amendment No. 2 thereto effective as of December 16, 2009, Amendment No. 3 thereto effective as of March 1, 2011, and Amendment No. 4 thereto effective as of March 28, 2014 (together, the “Employment Agreement”), by and between Wyndham Worldwide Corporation, a Delaware corporation (the “Company”), and Geoff Ballotti (the “Executive”).
WHEREAS, the Company and the Executive have previously entered into the Employment Agreement and desire to amend the Employment Agreement as set forth below.
NOW, THEREFORE, effective as of the date first written above, the Employment Agreement is hereby amended as follows:
1.The first sentence of Section II of the Employment Agreement is hereby amended in its entirety and replaced with the following:
The period of the Executive’s employment under this Agreement (the “Period of Employment”) shall begin on the Effective Date and shall end on March 31, 2020, subject to earlier termination as provided in this Agreement.
2.Section VII(f) of the Employment Agreement is hereby amended by adding the following sentence to the end thereof:  


Nothing in this Agreement is intended to or will be used in any way to limit the Executive’s rights to communicate with a government agency, as provided for, protected under or warranted by applicable law.  


3.From and after the date hereof, all references to the Employment Agreement shall mean the Employment Agreement as amended hereby.  Except as expressly amended hereby, the Employment Agreement shall remain in full force and effect, and is hereby ratified and confirmed. 
 [Signature Page Follows.]


1









IN WITNESS WHEREOF, the undersigned has caused this Amendment to be executed this 15th day of February 2017. 
EXECUTIVE
/s/ Geoff Ballotti                        
Geoff Ballotti
WYNDHAM WORLDWIDE CORPORATION
By:/s/ Mary Falvey                        
Name: Mary Falvey
Title: Executive Vice President




2
§ 310.509 Parenteral drug products in plastic containers. ( a ) Any parenteral drug product packaged in a plastic immediate container is not generally recognized as safe and effective, is a new drug within the meaning of section 201(p) of the act, and requires an approved new drug application as a condition for marketing. An “Investigational New Drug Application” set forth in part 312 of this chapter is required for clinical investigations designed to obtain evidence of safety and effectiveness.
( b ) As used in this section, the term “large volume parenteral drug product” means a terminally sterilized aqueous drug product packaged in a single-dose container with a capacity of 100 milliliters or more and intended to be administered or used intravenously in a human.
( c ) Until the results of compatibility studies are evaluated, a large volume parenteral drug product for intravenous use in humans that is packaged in a plastic immediate container on or after April 16, 1979, is misbranded unless its labeling contains a warning that includes the following information: ( 1 ) A statement that additives may be incompatible.
( 2 ) A statement that, if additive drugs are introduced into the parenteral system, aseptic techniques should be used and the solution should be thoroughly mixed.
( 3 ) A statement that a solution containing an additive drug should not be stored.
( d ) This section does not apply to a biological product licensed under the Public Health Service Act of July 1, 1944 (42 U.S.C. 201).
[62 FR 12084, Mar. 14, 1997]
OFFICIALNOTICE FROM COURT OF CRIMINALAPPEALS OF TEXAS P.O. BOX 12308, CAPITOL STATION, AUSTIN, TEXAS 78711 FILE COPY

-•


### 12/30/2015 COA No. 12-15-00214-CR 

### CORDERO-VARELA, JORGE Tr. Ct. No. 114-0767-12 PD-1383-15 

## The appellant's prose petition for discretionary reviewhas this day been received and filed. 

### Abel Acosta, Clerk 12TH COURT OF APPEALS CLERK PAM ESTES 

### 1517W. FRONT, ROOM 354 TYLER, TX 75701 * DELIVERED VIA E-MAIL *
#### § 510.106 Labeling of antibiotic and antibiotic-containing drugs intended for use in milk-producing animals.

Whenever the labeling of an antibiotic drug included in the regulations in this chapter suggests or recommends its use in milk-producing animals, the label of such drugs shall bear either the statement “Warning: Not for use in animals producing milk, since this use will result in contamination of the milk” or the statement “Warning: Milk that has been taken from animals during treatment and for __hours after the latest treatment must not be used for food”, the blank being filled in with the figure that the Commissioner has authorized the manufacturer of the drug to use. The Commissioner shall determine what such figures shall be from information submitted by the manufacturer and which the Commissioner considers is adequate to prove that period of time after the latest treatment that the milk from treated animals will contain no violative residues from use of the preparation. If the Commissioner determines from the information submitted that the use of the antibiotic drug as recommended does not result in its appearance in the milk, the Commissioner may exempt the drug from bearing either of the above warning statements.

[63 FR 32980, June 17, 1998]
msci-ex102_463.htm



 

Exhibit 10.2

Non-Employee Director Compensation
(Effective February 2017)

 


			
	
 
	
 
	
Retainer(1)

	
Annual Cash Retainer
	
 
	
$75,000

	
Annual Equity Retainer in Restricted Stock Units 
	
 
	
$140,000(2)

	
Lead Director Annual Equity Retainer in Restricted Stock Units
	
 
	
$165,000(2)

	

Committee Chair
	
 
	
 

	
Audit Committee
	
 
	
$25,000

	
Compensation & Talent Management Committee
	
 
	
$20,000

	
Strategy & Finance Committee 
	
 
	
$20,000

	
Nominating & Corporate Governance Committee
	
 
	
$15,000

	
 
	
 
	
 

	
Committee Non-Chair Member
	
 
	
 

	
Audit Committee
	
 
	
$10,000

	
Compensation & Talent Management Committee
	
 
	
$10,000

	
Strategy & Finance Committee
	
 
	
$10,000

	
Nominating & Corporate Governance Committee
	
 
	
$10,000

	
Strategy & Finance Committee
	
 
	
$10,000




 


	
	
 

 

(1)Each Board term commences on May 1st of the then-current year and concludes on April 30th of the following year. Accordingly, retainer fees are paid and restricted stock units are granted on May 1st of each year. Restricted stock units vest on the first anniversary of the grant date.

(2)The aggregate fair market value of the restricted stock units is based on the closing price of MSCI Inc.’s common stock as reported by The New York Stock Exchange on the date prior to the date of grant.




Members of the Board of Directors are subject to the Non-Employee Director Stock Ownership Guidelines, which are described in the MSCI Inc. Corporate Governance Policies available on the Investor Relations section of MSCI website’s (http://ir.msci.com). Information contained on the website is not incorporated by reference into this exhibit filed with the Quarterly Report on Form 10-Q or any other report filed with the SEC. Additional information regarding MSCI Inc.’s non-employee director compensation program is available in its proxy statement for its annual meeting of shareholders.
# OAR Box 1490 Prepped by Charmelle Mathews



## Document

Number: 

# 46 ) IV-C-1 9 Docket Number: 

# A-94-5 2

Printed 8/4/200811:51:47

AM Sheet 46 of 273 P. 1P. 2 A-94-5 2 IV-C-1 9 Keit h Barnet t 4 02/27/200 2 09:0 4 A M To : Joh n Schweitze r<jschwtzr@gte.net > cc : Subject : Re : Determinin g HA P content S I talke d t o Mark

an d reviewe d th e tex

t i n th e Boa

t Manufacturin g rule . I don' t see an yreaso n w e couldn' t adop t mos t o fthei rlanguag e o n organi cHA P conten t determination . Keit h W . Barnet

t US/EP AOAQPS , ESD/MIC G C504-05 Researc h Triangl e Park , N C 2771 1 919-541-560 5 barnett.keith@epa.gov Joh n Schweitze r<jschwtzr@gte.net > To : Keit h Barnett/RTP/USEPA/US@EP A cc : Subject : Determinin g HA P conten t

Keith , i n Sectio n V.R . (pag e 76 ) o fouNComments , wedske d yo u t o conside radoptio n ofth e sam e provision s a

s used i n th e boa

t rul e fo rsources to^pS

e i n determinin g th e HA

P conten t o f resi n an d ge l coat . kno wifyo u wil l mak

e th e chang e a

s w e suggested ?

FRO M Joh n Schweitz i Sr. Directo ro f Gov't . Affair s Composites Fabricator

s Asso c voic e 734.622.016 2 fa x7*4.622.012 2 ischwtzr@ate.net www.cfa-hq.or

o
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Series of Studies on Employment of Women in Various Defense Industries

              																								United States. Women's Bureau.						"Employing Women in Shipyards : Women's Bureau Bulletin, No. 192-6" in *Series of Studies on Employment of Women in Various Defense Industries : Women's Bureau Bulletin, No. 192*			(1944).						https://fraser.stlouisfed.org/title/5465/item/539658, accessed on September 25, 2024.	    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
§ 520.1331 Meclofenamic acid tablets. ( a ) *Specifications.* Each tablet contains either 10 or 20 milligrams of meclofenamic acid.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* 1.1 milligrams per kilogram (0.5 milligram per pound) daily for 5 to 7 days.
( 2 ) *Indications for use.* For the relief of signs and symptoms of chronic inflammatory disease involving the musculoskeletal system.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[50 FR 43385, Oct. 25, 1985, as amended at 53 FR 23390, June 22, 1988; 78 FR 28824, May 20, 2014]
[if !vml]>[endif]>

[if !vml]>[endif]>

You have reached the FederalDepository Library Program Electronic Collection (FDLP/EC) Archive. Thisarchive assures ongoing access to publications in the FDLP/EC. Access topublications in the archive is available through GPO's suite of cataloging andlocator services, including the Catalog of U.S. Government Publications(CGP).  Archived copies of publications are retrieved in the event thatpublications are no longer available from the original publishing agency site. 
**Title:****Cooperative statistics.**
 
2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014
 
SuDoc Number:A 109.11/2:
Item Number:0064-C-03 (online)
CGP systemNumber:000834821
 
January 30, 2020
UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF COLUMBIA

Crim. Action No. 05

- 00 272 (CKK)

ORDER

May 10 , 20 22

This case comes before the Court upon the receipt of a Report and Recommendation

dated April 25

, 2022 , from Magistrate Judge G. Michael Harvey. See ECF No. 59. No

objections to the Magistrate Judge’s Report and Recommendation have been received by the

Court.

Accordingly , it is this 10th day of May

, 20 22

,

ORDERED that the Report and Recommendation is hereby ADOPTED

. Defendant

Reginald Russell’s supervised release, which expired on March 23, 2022, shall be deemed

terminated as unsuccessful, and Defendant shall not be reincarcerat ed for his recent failed drug

tests.

_________ /s/

_____________________ COLLEEN KOLLAR

- KOTELLY

UNITED STATES D ISTRICT J UDGE UNITED STATES OF AMERICA,

v.

REGINALD RUSSELL

,

Defendant.
---

---

Exhibit 14.2

[BDO McCabe Lo Limited
Letterhead]

# CONSENT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by
reference in the Registration Statements on Form S-8 (File Nos. 333-102288 and 333-92491)
pertaining to the Employee Stock Option plans of Ellomay Capital Ltd. (the
Company) and Form F-3 (File Nos. 333-144171, 333-115826, 333-114428, 333-47842 and
333-92493) of the Company and in the related Prospectus of our report dated June 26, 2008
with respect to the financial statements of NUR Asia Pacific Limited included in the
Annual Report on Form 20-F of Ellomay Capital Ltd. for the year ended December 31, 2008.

/s/ BDO McCabe Lo Limited

BDO McCabe Lo LimitedCertified Public
Accountants

March 31, 2009



---

---
§ 349.79 Labeling of permitted combinations of active ingredients. Statements of identity, indications, warnings, and directions for use, respectively, applicable to each ingredient in the product may be combined to eliminate duplicative words or phrases so that the resulting information is clear and understandable. ( a ) *Statement of identity.* For a combination drug product that has an established name, the labeling of the product states the established name of the combination drug product, followed by the statement of identity for each ingredient in the combination, as established in the statement of identity sections of this part. For a combination drug product that does not have an established name, the labeling of the product states the statement of identity for each ingredient in the combination, as established in the statement of identity sections of this part.
( b ) *Indications.* The labeling of the product states, under the heading “Indications,” the indication(s) for each ingredient in the combination, as established in the indications sections of this part.
( c ) *Warnings.* The labeling of the product states, under the heading “Warnings,” the warning(s) for each ingredient in the combination, as established in the warnings sections of this part.
( d ) *Directions.* The labeling of the product states, under the heading “Directions,” directions that conform to the directions established for each ingredient in the directions sections of this part. When the time intervals or age limitations for administration of the individual ingredients differ, the directions for the combination product may not exceed any maximum dosage limits established for the individual ingredients in the applicable OTC drug monograph.
#### Patricia D. MATTISON, Petitioner, v. DEPARTMENT OF TRANSPORTATION, Respondent.

No. 05-3371.

United States Court of Appeals, Federal Circuit.

Oct. 24, 2005.

ORDER

The petitioner having failed to file the required Statement Concerning Discrimination, it is

ORDERED that the petition for review be, and the same hereby is, DISMISSED, for failure to prosecute in accordance with the rules.
<PAGE>

EXHIBIT 32(a)

     CERTIFICATION PURSUANT TO 18 U.S.C SECTION 1350, AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Northland Cable Properties Seven
Limited Partnership (the "Partnership") on Form 10Q for the period ended
September 30, 2003 as filed with the Securities and Exchange Commission on the
date hereof (the "Form 10-Q"), I, John Whetzell, Chief Executive Officer of
Northland Communications Corporation, the General Partner, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that;

         (1)      The Form 10-Q fully complies with the requirements of Section
                  13(a) or (15(d) of the Securities Exchange Act of 1934 (15
                  U.S.C. 78m or 78(d)); and

         (2)      The information contained in the Form 10-Q fairly presents in
                  all material respects, the financial condition and results of
                  operations of the Partnership.

DATE: 11-14-03

/s/ JOHN S. WHETZELL
    -----------------------------------
    John S. Whetzell
    Chief Executive Officer

A signed original of this written statement required by Section 906 has been
provided to Northland Cable Properties Seven Limited Partnership and will be
retained by Northland Cable Properties Seven Limited Partnership and furnished
to the Securities and Exchange Commission or its staff upon request.
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT No. 96-6998
LARRY DARNELL SPEARS, Plaintiff - Appellant, versus JAMES E. BRIGGS, Ombudsman Services Unit, Manager, Defendant - Appellee.Appeal from the United States District Court for the Eastern District of Virginia, at Alexandria. T.S. Ellis, III, District Judge. (CA-96-427-AM) Submitted: June 19, 1997 Decided: June 26, 1997 Before WILKINS and MICHAEL, Circuit Judges, and BUTZNER, Senior Circuit Judge. Dismissed by unpublished per curiam opinion. Larry Darnell Spears, Appellant Pro Se. Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).2 PER CURIAM: Appellant, a Virginia inmate, app eals the district court's order denying relief on his 42 U.S.C. § 1983 (1994) complaint under 28 U.S.C.A. § 1915A (West Supp. 1997). We have reviewed the recordand the district court's opinion and find that this appeal is frivolous. Accordingly, we dismiss the appeal on the reasoning of the district court. Spears v. Briggs , No. CA-96-427-AM (E.D. Va. Apr. 1, 1996). We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

DISMISSED